Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory prospective study of faricimab in diabetic macular edema
2020-001174-30Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Primary endpoint: Change in DRSS between day one and day 112. Started Jan 2021; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2020-001174-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001174-30.